

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51053 A1

(51) International Patent Classification⁷: A61K 31/557, 9/00, 47/18, A61P 15/10

(21) International Application Number: PCT/US01/00852

(22) International Filing Date: 10 January 2001 (10.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/480,738 10 January 2000 (10.01.2000) US

(71) Applicant: NEXMED HOLDINGS, INC. [US/US]; 350 Corporate Boulevard, Robbinsville, NJ 08891 (US).

(72) Inventors: YEAGER, James; 820 Warwick Road, Deerfield, IL 60015 (US). BUYUKTIMKIN, Nadir; 2313 Willow Creek, Lawrence, KS 68049 (US). BUYUKTIMKIN, Servet; 2313 Willow Creek, Lawrence, KS 68049 (US).

(74) Agent: ZIMMERMAN, Roger, P.; McDonnell Bochnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (national): AL, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/51053 A1

(54) Title: PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION

(57) Abstract: The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E₁ composition of a semi-solid consistency. The composition comprises prostaglandin E₁, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C₁ to C₈ alcohol, aliphatic C₂ to C₃₀ ester, an aliphatic C₈ to C₃₀ ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

- 1 -

PROSTAGLANDIN COMPOSITIONS AND METHODS OF
TREATMENT FOR MALE ERECTILE DYSFUNCTION

5 Technical Field of the Invention

This invention relates to the compositions and methods for treatment of erectile dysfunction, and more particularly to methods and pharmaceutical compositions for intranavicular administration of 10 vasodilator medicaments to the fossa navicularis of a patient.

Background of the Invention

The term "impotence" has been used to signify the inability of the male to attain and 15 maintain erection of the penis sufficient to permit satisfactory sexual intercourse. The term "erectile dysfunction" has been suggested as a more precise term "to signify an inability of the male to achieve an erect penis as part of the overall multifaceted 20 process of male sexual function." Droller, M. J. et al. Impotence. Consensus Development Conference Statement, National Institutes of Health (1993).

Erectile dysfunction may result from 25 psychological causes (psychogenic erectile dysfunction) or organic causes or a combination of both. Organic causes include physiological, nervous, vascular and hormonal pathologies or a combination thereof.

The normal physiology of an erection 30 involves nerve impulses that signal certain muscles to relax. These muscles, when contracted, restrict blood flow through arteries in the penis. When relaxed, the muscles permit a significant increase in blood flow. The increased blood flow engorges three 35 groups of erectile tissue within the penis with blood and the penis becomes less flaccid. The engorged erectile tissue and the muscle structure of the penis

- 2 -

depress adjacent veins, restricting the flow of blood out of the penis. The restriction of blood flow out of the penis increases and sustains the erection.

Deficiencies of some hormones, such as 5 testosterone, or elevation of others, such as prolactin, can cause erectile dysfunction. Many drugs, such diuretics, antihypertensives, anticonvulsants, narcotics, alcohol, and psychotropic drugs may cause erectile dysfunction as a side 10 effect. Murray, F. T. et al. Amer. J. Medical Sci. 309: 99-109 (1995).

Damage to nerves and blood vessels may also provide an organic cause for erectile dysfunction. Disease processes may involve several aspects. For 15 example, diabetes, which causes damage to both nerves and blood vessels, can cause erectile dysfunction. A significant percent of all diabetic men will suffer from erectile dysfunction.

Methods proposed for the treatment of 20 erectile dysfunction have included external devices, sex therapy, surgical implantation of internal prostheses, injection of drugs directly into the penis and topically applied medications. None of these approaches is entirely effective.

External devices include tourniquets (see 25 U.S. Pat. No. 2,818,855) and externally applied vacuum erection aids. While some clinicians consider externally applied erection aids as a first option for treatment, some patients are unwilling to use 30 such devices. O'Keefe, M., et al. Medical Clinics of North America 79: 415-434 (1995).

Symptomatic sex therapy was originally found to be effective by Masters and Johnson, but later studies have not shown as impressive results. 35 Freudian therapy does not appear to patients to be an attractive alternative. Vickers, M. A., et al. J. Urology 149: 1258-1261 (1993).

- 3 -


Surgically implanted mechanical devices, such as hinged or solid rods and inflatable, spring driven or hydraulic prostheses have been used for some time.

5 The administration of erection effecting and enhancing drugs is taught in U.S. Pat. No. 4,127,118 to LaTorre. This patent teaches a method of treating male impotence by injecting into the penis an appropriate vasodilator, in particular, an 10 adrenergic blocking agent or a smooth muscle relaxant to effect and enhance an erection.

More recently, U.S. Pat. No. 4,801,587 to Voss et al. teaches the application of an ointment to relieve impotence. The ointment consists of the 15 vasodilators papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine, or phentolamine and a carrier to assist absorption of the primary agent through the skin. U.S. Pat. No. 5,256,652 to El-Rashidy teaches the use of an aqueous topical 20 composition of a vasodilator such as papaverine together with hydroxypropyl- β -cyclodextrin.

Prostaglandin E₁ is a derivative of prostanoic acid, a 20-carbon atom lipid acid, represented by the formula:

25



and is commercially available, e.g., from Chinoim Pharmaceutical and Chemical Works Ltd. (Budapest, Hungary) under the designation "Alprostadil USP," 30 from Phamacia & Upjohn under the designation

- 4 -

"Caverject" and from The Upjohn Company (Kalamazoo, Michigan) under the designation "Prostin VR."

5 Prostaglandin E₁ is a vasodilator useful to maintain open blood vessels and therefore, to treat peripheral vascular disease among other ailments. While the potential benefits from transdermal delivery of prostaglandin E₁ have long been recognized, prior efforts at developing a topical composition for prostaglandin delivery have not been 10 fully successful.

In one commercially available form (MUSE[®], Vivus, Menlo Park CA), alprostadil is administered in a pellet deposited in the urethra using an applicator with a hollow stem 3.2 cm in length and 3.5 mm in 15 diameter (Padma-Nathan, H., et al., N. Engl. J. Med., 336: 1-7 (1997), see especially Fig. 1). In the home treatment portion of the Padma-Nathan et al. study, 32.7% of the patients (10.8% of administrations) receiving MUSE[®] complained of penile pain and 5.1% 20 experienced minor urethral trauma, compared to 3.3% and 1.0%, respectively, of the patients receiving placebo. Frequency of report of these side effects has varied in subsequent studies: MUSE[®] producing 25 penile pain in 17-23.6% of administrations, compared to 1.7% with placebo and minor urethral bleeding reported by 4.8% of patients (Peterson, C.A., et al., J. Urol., 159: 1523-1528 (1998)). In a study on a European population, 31% MUSE[®] patients reporting 30 penile pain or burning sensations, 4.8% reporting urethral bleeding, and 2.9% reporting severe testicular pain (Porst, H., Int. J. Impot. Res., 9:187-192 (1997)). The percent of patients responding to MUSE[®] treatment, defined as having at least one 35 erection considered sufficient for intercourse, has been reported to be 43% (Porst, 1997), 65.9% (Padma-Nathan et al., 1997) and 70.5% (Peterson et al., 1998), although published editorial comment has

- 5 -

suggested that the percent of patients responding in the latter two studies is more properly reported as 30-40% (Benson, G., J. Urol., 159: 1527-1528 (1998)).

In particular, there is presently no 5 commercial source for a topical semi-solid formulation that is useful without a supporting device such as a patch, adhesive strip, and the like. For example, U.S. Patent No. 5,380,760 to Wendel et al. is directed to a topical prostaglandin 10 formulation that includes a pressure-sensitive, adhesive sheet of polyisobutylene.

Working alone most drugs, prostaglandin formulations included, do not sufficiently permeate the skin to provide drug concentration levels 15 comparable to those obtained from other drug delivery routes. To overcome this problem, topical drug formulations typically include a skin penetration enhancer. Skin penetration enhancers also may be referred to as absorption enhancers, accelerants, 20 adjuvants, solubilizers, sorption promoters, etc. Whatever the name, such agents serve to improve drug absorption across the skin. Ideal penetration enhancers not only increase drug flux across the skin, but do so without irritating, sensitizing, or 25 damaging skin. Furthermore, ideal penetration enhancers should not adversely affect the physical qualities of the available dosage forms (e.g. cream or gel), or the cosmetic quality of the topical composition.

30 A wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, *Percutaneous Penetration Enhancers*, Maibach H. I. and Smith H. E. (eds.), CRC Press, 35 Inc., Boca Raton, F.L. (1995), which surveys the use and testing of various skin penetration enhancers, and Büyüktimkin et al., *Chemical Means of Transdermal*

- 6 -

Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems , Gosh T.K., Pfister W.R., Yum S.I. (Eds.), Interpharm Press Inc., Buffalo Grove, I.L. (1997) .

5 A fully successful topical or transmucosal formulation for prostaglandin E₁ has not yet been identified and commercially available. Unfortunately, prostaglandin E₁ is readily transformed by rearrangement and other reactions. This relative 10 instability tends to complicate efforts at formulating composition for intranavicular delivery.

15 The present invention addresses these problems by providing a method and compositions for the intranavicular delivery of semi-solid, separation- resistant and chemically stable composition for the relatively rapid, sustained 20 delivery of a vasodilator, preferably prostaglandin E₁.

25 Summary of the Invention

The present invention provides methods and compositions for the treatment of erectile dysfunction by the intranavicular application of pharmaceutical compositions to the mammalian penis.

30 The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E₁ composition of a semi-solid consistency. The composition comprises a vasodilator, preferably prostaglandin E₁, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2- (N,N-disubstituted amino)-alkanoate ester, an 35 (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C₁ to C₈ alcohol, an aliphatic C₂ to C₃₀

- 7 -

ester, aliphatic C₈ to C₃₀ ester or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

5 Intranavicular placement of the vasodilator composition of the present invention, i.e., within in the fossa navicularis, provides a number of advantages over placing such compositions on the skin surface of the penis or depositing a composition 10 within the more proximal "pars spongiosa" portion of the urethra. The fossa navicularis is a natural expanded chamber suitably adapted to receive and retain semisolid medicaments. A semi-solid medicament, such as the composition of the present 15 invention, when placed in the fossa has higher impedance to flow at narrowed exits of this space, the meatus and the urethra. The impedance to flow is proportional to the product of the cross sectional area of the path and the path length.

20 The lining of the fossa navicularis is a non-keratinized stratified squamous epithelium, thereby providing for enhanced permeability compared to the keratinized epithelium of the surface skin of the outside of the penis.

25 The use of a short applicator that has a tip that ends within the anatomical limits of the fossa navicularis is less invasive than threading a longer applicator several centimeters up (or proximal) into the penile urethra proper. Preferably, the applicator 30 comprises a reservoir containing an erection inducing amount of a semi-solid prostaglandin E₁ composition.

35 More preferably, the applicator is a single use device and contains a single dose of the semi-solid prostaglandin E₁ composition. The applicator is typically packed with instructions for use placed on all or some of the following; on the package containing the applicator, in a package insert and on

- 8 -

the outside surface of the applicator itself.

The high glycogen content and bacterial flora within the fossa navicularis provides a naturally lower pH within the space, so that lower pH compositions that provide for high solubility of prostaglandin E1 can be more easily tolerated without excessive irritation of the tissues.

The fossa navicularis is also a more immunologically protected site than the adjacent pars spongiosa region of the penile urethra proper.

Placing the tip of an applicator within the anatomical limits of the fossa navicularis thus presents less of a risk of circumventing the natural barriers to disease by artificially transporting contaminants, e.g., from the surface of the penis, directly into the penile urethra proper.

A pharmaceutical composition suitable for intranavicular application comprises prostaglandin E₁, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4. If desired, stabilizers, preservatives and emulsifiers may be included.

Compositions of the present invention can take the form of a semi-solid suitable for intranavicular application. In use as a intranavicular agent, these compositions exhibit relatively high prostaglandin penetration and bioavailability without requiring a wasteful overloading prostaglandin concentration. The

- 9 -

composition further exhibit reduced irritation, sensitivity and damage of local tissues. In a preferred embodiment, the compositions are delivered to the fossa navicularis using an suitable single dose applicator.

5 Other and further aims, purposes, features, advantages, embodiments and the like will be apparent to those skilled in the art from the present specification and the appended claims.

- 10 -

Brief Description of the Drawings

In the drawings,
5 FIGURE 1 is a diagram of the anatomical structure of the human penis in longitudinal section view;

FIGURE 2 is a diagram of the anatomical details of the distal portion of the human penis in longitudinal section view;

10 FIGURE 3 is a graph of the cumulative prostaglandin E₁ penetration through shed snake skin of seven prostaglandin E₁ compositions prepared according to the present invention; and

15 FIGURE 4 is a comparison graph of the cumulative prostaglandin E₁ penetration through shed snake skin of two prostaglandin E₁ compositions prepared according to the present invention and two comparative compositions.

Detailed Description of the Preferred Embodiments

20 It has been unexpectedly found that that a semi-solid prostaglandin E₁ composition suitable for the treatment of erectile dysfunction can be placed advantageously in a natural enlarged space immediately proximal to the penile meatus, the fossa navicularis.

30 The fossa navicularis provides a restricted site that is ideally suited for the application of pharmaceutical compositions. The space is lined by a non-keratinized stratified squamous epithelium and is thereby distinguished from the surface skin covering the glans and the rest of the penis and from the stratified columnar epithelium of the lining of the urethra proper. It has been found that the administration of the composition of the present 35 invention in the fossa navicularis has unexpectedly high efficacy and low incidence of local side effects.

- 11 -

The fossa navicularis provides a natural space adaptable to the application and retention of pharmaceutical compositions. A semi-solid medicament, such as the composition of the present invention, when placed in the fossa has higher impedance to flow at narrowed exits of this space, the meatus and the urethra. Thus, a semi-solid medication of suitably chosen viscosity is naturally retained within the fossa, facilitating the absorption of active agents such as vasodilators.

The fossa navicularis is part of the natural defense system that protects the body against infection. The fossa navicularis is a more immunologically protected site than the adjacent pars spongiosa region of the penile urethra proper. Depositing a semisolid medicament within the anatomical limits of the fossa navicularis thus does not circumvent the natural barriers to disease by artificially transporting contaminants, e.g., from the surface of the penis, directly into the penile urethra proper. As noted above, the fossa navicularis naturally supports a bacterial flora that maintains an acid pH.

Referring to FIGURE 1, the basic structure of the human penis is illustrated. The fossa navicularis 110 is a natural enlargement of the lumen of the male urethra that extends distally to the urethral meatus 128 and proximally to the pendulous region of the urethra 112 (also termed "pars spongiosa" region of the urethra), the portion of the urethra that passes through the corpus spongiosum 134. The bulbar urethra 114 is proximal to the pendulous region of the urethra, and passes through the bulbospongiosus muscle 140. More proximally, the opening 148 in the wall of the urethra of the bulbourethral glands (Cowper's glands) can be seen. More proximally, the urethra passes through the

- 12 -

prostate gland 160, where openings ejaculatory duct 156 and of the prostate utricle 158 are visible in wall of the urethra.

Referring to FIGURE 2, the detailed structure of the fossa navicularis 110 is illustrated. The external opening of the urethral meatus 128 is the distal limit of the fossa navicularis. The external skin of the glans is covered by a keratinized stratified squamous epithelium 186 (Pudney, J., and Anderson, D.J., 1995) Immunobiology of the human penile urethra, Amer. J. Path., 147: 155-165) that is marked by proximally by a sharp transition (dashed line) to the nonkeratinized stratified squamous epithelium without glycogen 184 that is characteristic of the lining of the distal fossa navicularis.

The fossa navicularis widens proximally and the lining changes to a nonkeratinized stratified squamous epithelium with glycogen 182. The glycogen in this region is believed to support a bacterial flora that lowers the pH of the region and contributes to a natural defense against infection. Holstein, A.F., et al., (1991) Different epithelia in the distal human male urethra, Cell Tiss. Res. 264: 23-32. This nonkeratinized stratified squamous epithelium with glycogen is under hormonal control, and increases in extent under increased estrogen levels. (Holstein, et al., 1991. The proximal fossa navicularis narrows in width, and is lined by a stratified columnar epithelium 180.

The method of the present invention also provides a relatively non-invasive applicator. When used to place an effective erection-inducing amount of a prostaglandin E1 composition within the fossa navicularis, the tip of the applicator does not extend beyond the anatomical limits of the fossa navicularis. Preferably, the tip of the applicator

- 13 -

does not extend into the penis more than about two centimeters beyond the meatal opening, more preferably no more than about 2 centimeter, most preferably no more than about 0.5 centimeters.

5 Preferably, the applicator comprises a reservoir containing an erection inducing amount of a semi-solid composition comprising at least one vasodilator, preferably a prostaglandin E1 composition. More preferably, the applicator is a

10 single use device and contains a single dose of the semi-solid vasodilator composition. The applicator is typically packed with instructions for use placed on all or some of the following; on the package containing the applicator, in a package insert and on

15 the outside surface of the applicator itself.

The pharmaceutical composition of the present invention comprises at least one vasodilator, preferably prostaglandin E₁, an alkyl (N,N-disubstituted amino) ester, a polysaccharide gum, a lipophilic compound, and an acid buffer system.

Suitable vasoactive agents include, but are not limited to: nitrates such as nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, sodium nitroprusside, molsidomine, linsidomine chlorhydrate ("SIN-1") and S-nitroso-N-acetyl-d,l-penicillamine ("SNAP"); amino acids such as L-arginine; long and short acting α -blockers such as phenoxybenzamine, dibenamine, doxazosin, terazosin, phentolamine, tolazoline, prazosin, trimazosin, alfuzosin, tamsulosin and indoramin; vasodilative natural herbal compositions and bioactive extracts thereof, such as gosyajinki-gan, Satureja obovata, bai-hua qian-hu, lipotab, saiboku-to, vincopetine, Gingko biloba, bacopa, Gynostemma pentaphyllum, gypenosides, Evodia rutaecarpa, rutaecarpine, dehydroevodiamine, dan-shen, salviae miltiorrhizae radix, shosaikoto, Zizyphi fructus,

ginseng and mixtures thereof (U.S. Patent 6,007,824); ergot alkaloids such as ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianergoline, delorgotrile,
5 disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergctamine, nicergoline, pergolide, propisergide, proterguride and terguride; antihypertensive agents such as diazoxide,
10 hydralazine and minoxidil; vasodilators such as nimodepine, pinacidil, cyclandelate, dipyridamole and isoxsuprine; chlorpromazine; haloperidol; yohimbine; trazodone; naturally occurring prostaglandins such as PGE₁, PGA₁, PGB₁, PGF_{1 α} , 19-hydroxy-PGA₁, 19-hydroxy-
15 PGB₁, PGE₂, PGA₂, PGB₂, 19-hydroxy-PGA₂, 19-hydroxy-PGB₂, PGE₃, PGF_{3 α} ; semisynthetic or synthetic derivatives of natural prostaglandins, including carboprost tromethamine, dinoprost tromethamine, dinoprostone, lipoprost, gemeprost, metenoprost,
20 sulprostone and tiaprost; and vasoactive intestinal peptides. Prazosin, prostaglandin E₁ and prostaglandin E₂ are particularly preferred vasoactive agents for use in conjunction with the present method. Additionally, simultaneous administration of two or
25 more vasoactive agents may be desirable and may in some cases exhibit a synergistic effect. The combination of prazosin with prostaglandin E₁ has been found to be particularly advantageous in this regard; the latter drug appears to act a permeation enhancer for prazosin, i.e., it increases the rate at which prazosin permeates through the skin or mucosal tissue and enters the bloodstream.

30 Prostaglandin E₁ is well known to those skilled in the art. Reference may be had to various literature references for its pharmacological activities, side effects, and normal dosage ranges.

- 15 -

See for example, *Physician's Desk Reference*, 51st Ed. (1997), *The Merck Index*, 12th Ed., Merck & Co., N.J. (1996), and *Martindale The Extra Pharmacopoeia*, 28th Ed., London, The Pharmaceutical Press (1982).


5 Prostaglandin E₁ as well as other compounds referenced herein are intended to encompass pharmaceutically acceptable derivatives including physiologically compatible salts and ester derivatives thereof.

The quantity of prostaglandin E₁ in the pharmaceutical compositions of the present invention is a therapeutically effective amount and necessarily varies according to the desired dose, the dosage form (e.g., suppository or topical), and the particular form of prostaglandin E₁ used. The term "prostaglandin" as used generically herein refers to the prostaglandin free acid and pharmaceutically acceptable derivatives thereof, including PGE₁, pharmaceutically acceptable salts and lower alkyl esters thereof (the term "lower alkyl" as used herein means straight chain or branched chain alkyl containing one to four carbon atoms). The composition generally contains between 0.001 percent to 1 percent prostaglandin E₁, typically contains between 0.05 percent to 1 percent prostaglandin E₁, preferably from 0.1 percent to 0.5 percent, based on the total weight of the composition.

An important component of the present invention is the penetration enhancer. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. For convenient reference, alkyl-2-(N,N-disubstituted amino)-alkanoates and (N,N-disubstituted amino)-alkanol alkanoates can be grouped together under the label alkyl (N,N-disubstituted amino) esters.

- 16 -


Alkyl-2-(N,N-disubstituted amino)-alkanoates suitable for the present invention can be represented as follows:



5


wherein n is an integer having a value in the range of about 4 to about 18; R is a member of the group consisting of hydrogen, C₁ to C₇ alkyl, benzyl and phenyl; R₁ and R₂ are members of the group consisting of hydrogen and C₁ to C₇ alkyl; and R₃ and R₄ are members of the group consisting of hydrogen, methyl and ethyl.

Preferred alkyl (N,N-disubstituted amino)-alkanoates are C₄ to C₁₈ alkyl (N,N-disubstituted amino)-acetates and C₄ to C₁₈ alkyl (N,N-disubstituted amino)-propionates and pharmaceutically acceptable salts and derivatives thereof. Exemplary specific alkyl-2-(N,N-disubstituted amino)-alkanoates include dodecyl 2-(N,N dimethylamino)-propionate (DDAIP);



20

and dodecyl 2-(N,N-dimethylamino)-acetate (DDAA) ;




5

Alkyl-2-(N,N-disubstituted amino)-alkanoates are known. For example, dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP) is available from 10 Steroids, Ltd. (Chicago, IL). In addition, alkyl-2-(N,N-disubstituted amino)-alkanoates can be synthesized from more readily available compounds as described in U.S. Patent No. 4,980,378 to Wong et al., which is incorporated herein by reference to the 15 extent that it is not inconsistent. As described therein, alkyl-2-(N,N-disubstituted amino)-alkanoates are readily prepared via a two-step synthesis. In the first step, long chain alkyl chloroacetates are prepared by reaction of the corresponding long chain 20 alkanols with chloromethyl chloroformate or the like in the presence of an appropriate base such as triethylamine, typically in a suitable solvent such as chloroform. The reaction can


- 18 -

be depicted as follows:



wherein R, R₃, R₄ and n are defined as above. The reaction temperature may be selected from about 10 degrees Celsius to about 200 degrees Celsius or reflux, with room temperature being preferred. The use of a solvent is optional. If a solvent is used, a wide variety of organic solvents may be selected. Choice of a base is likewise not critical. Preferred bases include tertiary amines such as triethylamine, pyridine and the like. Reaction time generally extends from about one hour to three days.

In the second step, the long chain alkyl chloroacetate is condensed with an appropriate amine according to the scheme:




wherein n, R, R₁, R₂, R₃ and R₄ are defined as before. Excess amine reactant is typically used as the base and the reaction is conveniently conducted in a

- 19 -


suitable solvent such as ether. This second step is preferably run at room temperature, although temperature may vary. Reaction time usually varies from about one hour to several days. Conventional 5 purification techniques can be applied to ready the resulting ester for use in a pharmaceutical compound.

Suitable (N,N-disubstituted amino)-alkanol alkanoates can be represented by the formula:




10 wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are members of the group consisting of hydrogen, C₁ to C₈ alkyl, and C₁ to C₈ aryl; and R₈ is 15 a member of the group consisting of hydrogen, hydroxyl, C₁ to C₈ alkyl, and C₁ to C₈ aryl.

Preferred (N,N-disubstituted amino)-alkanol alkanoates are C₅ to C₁₈ carboxylic acid esters and pharmaceutically acceptable salts thereof. Exemplary 20 specific (N,N-disubstituted amino)-alkanol alkanoates include 1-(N,N-dimethylamino)-2-propanol dodecanoate (DAIPD);




1-(N,N-dimethylamino)-2-propanol myristate (DAIPM);

- 20 -



1- (N,N-dimethylamino) -2-propanol oleate (DAIPO) ;



5

The (N,N-disubstituted amino)-alkanol alkanoates are readily prepared by reacting the corresponding aminoalkinol with lauroyl chloride in the presence of triethylamine. A solvent such as chloroform is optional but preferred. For example, 1- (N,N-dimethylamino) -2-propanol can be reacted with lauroyl chloride in chloroform and in the presence of triethylamine to form 1- (N,N-dimethylamino) -2-propanol dodecanoate (DAIPD).

15 Among the suitable penetration enhancers for the present invention DDAIP is generally preferred.

The penetration enhancer is present in an amount sufficient to enhance the penetration of the 20 prostaglandin E₁. The specific amount varies necessarily according to the desired release rate and the specific form of prostaglandin E₁ used. Generally, this amount ranges from about 0.5 percent to about 10 percent, based on the total weight of the 25 composition. Preferably, the penetration enhancer is about 5 weight percent of the composition.

- 21 -

Natural and modified polysaccharide gums are also an important ingredient to the present composition. Suitable representative gums are those in the natural and modified galactomannan gum category. A galactomannan gum is a carbohydrate polymer containing D-galactose and D-mannose units, or other derivatives of such a polymer. There is a relatively large number of galactomannans, which vary in composition depending on their origin. The galactomannan gum is characterized by a linear structure of β -D-mannopyranosyl units linked (1 \rightarrow 4). Single membered α -D-manopyranosyl units, linked (1 \rightarrow 6) with the main chain, are present as side branches. Galactomannan gums include guar gum, which is the pulverized endosperm of the seed of either of two leguminous plants (*Cyamopsis tetragonolobus* and *psoraloids*) and locust bean gum, which is found in the endosperm of the seeds of the carobtree (*ceratonia siliqua*). Locust bean gum is preferred for the present invention.

Suitable modified polysaccharide gums include ethers of natural or substituted polysaccharide gums, such as carboxymethyl ethers, ethylene glycol ethers and propylene glycol ethers. An exemplary substituted polysaccharide gum is methylcellulose.

Other suitable representative gums include agar gum, carrageenan gum, ghatti gum, karaya gum, rhamsan gum and xanthan gum. The composition of the present invention may contain a mixture of various gums, or mixture of gums and acidic polymers.

Gums, and galactomannan gums in particular, are well-known materials. See for instance, *Industrial Gums: Polysaccharides & Their Derivatives*, Whistler R. L. and BeMiller J.N. (eds.), 3rd Ed. Academic Press (1992) and Davidson R. L., *Handbook of*

- 22 -

5 *Water-Soluble Gums & Resins*, McGraw-Hill, Inc., N.Y. (1980). Most gums are commercially available in various forms, commonly a powder, and ready for use in foods and topical compositions. For example, locust bean gum in powdered form is available from Tic Gums Inc. (Belcam, MD).

10 When present, the polysaccharide gums are present in the range from about 0.1 percent to about 5 percent, based on the total weight of the composition, with the preferred range being from 0.5 percent to 3 percent. In one preferred embodiment, 2.5 percent by weight of a polysaccharide gum is present. Illustrative compositions are given in the examples, below.

15 An optional alternative to the polysaccharide gum is a polyacrylic acid polymer. A common variety of polyacrylic acid polymer is known generically as "carbomer." Carbomer is polyacrylic acid polymers lightly cross-linked with polyalkenyl polyether. It is commercially available from the B. F. Goodrich Company (Akron, Ohio) under the designation "CARBOPOL™." A particularly preferred variety of carbomer is that designated as "CARBOPOL 940."

25 Other polyacrylic acid polymers suitable for use in practicing this invention are those commercially available under the designations "Pemulen™" (B. F. Goodrich Company) and "POLYCARBOPHIL™" (A.H. Robbins, Richmond, VA). The 30 Pemulen™ polymers are copolymers of C₁₀ to C₃₀ alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol. The POLYCARBOPHIL™ 35 enhancer is a polyacrylic acid cross-linked with divinyl glycol.

Where polyacrylic acid polymers are present, they represent about 0.5 percent to about 5 percent of the composition, based on its total weight.

5 Another important component of the present invention is a lipophilic compound. In one embodiment, the lipophilic compound as used herein refers to an agent that is both lipophilic and hydrophilic. The C₁ to C₈ aliphatic alcohols, the 10 C₂ to C₃₀ aliphatic esters, and their mixtures can serve as lipophilic compound. Illustrative suitable alcohols are ethanol, n-propanol and isopropanol, while suitable esters are ethyl acetate, butyl acetate, ethyl laurate, methyl propionate, isopropyl 15 myristate and isopropyl palmitate. As used herein, the term "aliphatic alcohol" includes polyols such as glycerol, propylene glycol and polyethylene glycols. A mixture of alcohol and ester is preferred, and in particular, a mixture of ethanol and ethyl laurate 20 myristate is preferred.

In one embodiment, the C₂ to C₃₀ aliphatic esters, and their mixtures comprising the lipophilic compound include C₈ to C₃₀ aliphatic esters of glycerol selected from the group consisting 25 monoglycerides, diglycerides, triglycerides, and mixtures thereof. Suitable aliphatic esters include glyceryl esters of saturated fatty acids, unsaturated fatty acids and mixtures thereof. Suitable saturated fatty acids include caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid and lignoceric acid. Suitable unsaturated fatty acids include oleic acid, linoleic acid and linolenic acid. Suitable glyceryl esters include glyceryl 30 monooleate, triolein, trimyristin and tristearin, preferably trimyristin.

The concentration of lipophilic compound

required necessarily varies according to other factors such as the desired semi-solid consistency and the desired skin penetration promoting effects. Suitably the concentration of lipophilic compound is 5 in the range of 0.5 percent to 40 percent by weight based on the total weight of the composition. The preferred topical composition contains lipophilic compound in the range of 7 percent to 40 percent by weight based on the total weight of the composition.

10 Where a mixture of aliphatic alcohol and aliphatic ester are employed, the suitable amount of alcohol is in the range of 0.5 percent to 10 percent. In one preferred embodiment, the amount of alcohol is in the range of 5 percent to 15 percent, while that of 15 aliphatic ester is in the range from 2 percent to 15 percent (again based on the total weight of the composition). In another preferred embodiment, the amount of alcohol is in the range of 0.5 percent to 10 percent, while that of aliphatic ester is in the range from 0 percent to 10 percent (again based on 20 the total weight of the composition).

An optional, but preferred, component of the present invention is an emulsifier. Although not a critical factor, a suitable emulsifier generally 25 will exhibit a hydrophilic-lipophilic balance number greater than 10. Sucrose esters, and specifically sucrose stearate, can serve as emulsifiers for the topical composition of the present invention. Sucrose stearate is a well known emulsifier available 30 from various commercial sources. When an emulsifier is used, sucrose stearate present up to about 2 percent, based on the total weight of the composition, is preferred. The preferred amount of sucrose stearate emulsifier can also be expressed as 35 a weight ratio of emulsifier to polysaccharide gum. A ratio of 1 to 6 emulsifier to gum is preferred, and a ratio of 1 to 4 is most preferred to generate the

desired semi-solid consistency and separation resistance.

Other emulsifiers are also suitable including polyoxyethylene sorbitan esters, long chain alcohols, preferably cetostearyl alcohol, and fatty acid glycerides. Suitable polyoxyethylene sorbitan esters include the monolaurate (Tween 20, Span 20) the monopalmitate (Tween 40), the monostearate (Tween 60), and the monooleate (Tween 80) and mixtures thereof. Preferred fatty acid glycerides include glyceryl monooleate, triolein, trimyristin and tristearin.

The present invention includes an acid buffer system. Acid buffer systems serve to maintain or buffer the pH of compositions within a desired range. The term "buffer system" or "buffer" as used herein has reference to a solute agent or agents which, when in a water solution, stabilize such solution against a major change in pH (or hydrogen ion concentration or activity) when acids or bases are added thereto. Solute agent or agents which are thus responsible for a resistance to change in pH from a starting buffered pH value in the range indicated above are well known. While there are countless suitable buffers, potassium phosphate monohydrate has proven effective for compositions of the present invention.

The final pH value of the pharmaceutical composition of the present invention may vary within the physiologically compatible range. Necessarily, the final pH value is not irritating to human skin. Without violating this constraint, the pH may be selected to improve prostaglandin E₁ stability and to adjust consistency when required. In one embodiment, the preferred pH value is about 3.0 to about 7.4, more preferably about 3.0 to about 6.5, most preferably from about 3.5 to about 6.0.

5 The remaining component of the composition is water, which is necessarily purified. The composition contains water in the range of about 50 to about 90 percent, based on the total weight of the composition. The specific amount of water present is not critical, however, being adjustable to obtain the desired consistency and/or concentration of the other components.

10 Additionally, known transdermal penetration enhancers can also be added, if desired.

15 Illustrative are dimethyl sulfoxide (DMSO), dimethyl acetamide (DMA), 2-pyrrolidone, N,N-diethyl-m-toluamide (DEET), 1-dodecylazacycloheptane-2-one (Azone™, a registered trademark of Nelson Research), N,N-dimethylformamide, N-methyl-2-pyrrolidone, calcium thioglycolate, oxazolidinone, dioxolane derivatives, laurocapram derivatives, and macrocyclic enhancers such as macrocyclic ketones.

20 Prostaglandin E₁ stabilizers, coloring agents, rheological agents, and preservatives can be added to the extent that they do not overly limit prostaglandin E₁ skin penetration or prevent the desired semi-solid consistency.

25 Contemplated dosage forms of the semi-solid pharmaceutical composition of the present invention are creams, gels, ointments, colloidal suspensions and the like, also including but not limited to compositions suitable for use with transdermal patches and like devices.

30 The ingredients listed above may be combined in any order and manner that produces a stable composition comprising a prostaglandin E₁ evenly dispersed throughout a semi-solid formulation. One available approach to preparing such compositions 35 involves evenly dispersing the polysaccharide gum (or polyacrylic acid) in a premixed water/buffer solution and then thoroughly homogenizing (i.e. mixing) the

resulting mixture, which will be labelled "Part A." When present, the emulsifier is added to the water/buffer solution before dispersing the polysaccharide gum. Any suitable method of adjusting 5 the pH value of Part A to the desired level may be used, for example, by adding concentrated phosphoric acid or sodium hydroxide.

Separately, the prostaglandin E₁ is dissolved with agitation in the lipophilic compound, 10 which itself may be a mixture of alcohols, esters, or alcohol with ester. Next, the penetration enhancer is added. Alternatively, when the lipophilic compound includes both an alcohol and an ester, the prostaglandin E₁ can be dissolved in the alcohol 15 before adding the penetration enhancer followed by the ester. In either case, the resulting mixture will be labelled "Part B." The final step involves slow addition (e.g. dropwise) of Part B into Part A under constant mixing.

20 The resulting topical composition, when compared to exhibits the advantageous properties described above, including improved prostaglandin E₁ permeation and bioavailability without drug overloading, reduced skin damage and related 25 inflammation, and increased flexibility in design of dosage forms. These compositions can be used for prolonged treatment of peripheral vascular disease, male impotency and other disorders treated by prostaglandin E₁, while avoiding the low 30 bioavailability and rapid chemical decomposition associated with other delivery methods. Application of prostaglandin E₁ in a topical composition of the present invention to the skin of a patient allows a predetermined amount of prostaglandin E₁ to be 35 administered continuously to the patient and avoids undesirable effects present with a single or multiple administrations of larger dosages by injection. By

maintaining a sustained dosage rate, the prostaglandin E₁ level in the patient's target tissue can be better maintained within the optimal therapeutic range.

5 In one embodiment, the present invention provides a composition comprising about 0.01 percent to about 5 percent modified polysaccharide gum; about 0.001 percent to about 1 percent of a prostaglandin selected from the group consisting of PGE₁,

10 pharmaceutically acceptable salts thereof, lower alkyl esters thereof and mixtures thereof; about 0.5 percent to about 10 percent DDAIP or salts thereof; about 0.5 percent to about 10 percent of a lower alcohol selected from the group consisting of

15 ethanol, propanol, isopropanol and mixtures thereof; about 0.5 percent to about 10 percent on an ester selected from the group consisting of ethyl laurate, isopropyl myristate, isopropyl laurate and mixtures thereof; based on the weight of the composition, and

20 an acid buffer. Preferably the composition also comprises up to about 2 percent sucrose stearate.

Optionally the composition also comprises up to about 5 percent emulsifier. Preferably, the composition also comprises up to about 2 percent emulsifier. Suitable emulsifiers include glyceryl monooleate, triolein, trimyristin and tristearin. Preferred emulsifier is trimyristin.

The practice of the present invention is demonstrated in the following examples. These examples are meant to illustrate the invention rather than to limit its scope. Variations in the treating compositions which do not adversely affect the effectiveness of prostaglandin E₁ will be evident to one skilled in the art, and are within the scope of this invention. For example, additional ingredients such as coloring agents, anti-microbial preservatives, emulsifiers, perfumes, prostaglandin E₁

- 29 -

stabilizers, and the like may be included in the compositions as long as the resulting composition retains desirable properties, as described above. When present, preservatives are usually added in amounts of about 0.05 to about 0.30%. Suitable preservatives include methylparabens (methyl PABA), propylparabens (propyl PABA) and butylhydroxy toluene (BHT). Suitable perfumes and fragrances are known in the art; a suitable fragrance is up to about 5 percent myrtenol, preferably about 2 percent myrtenol, based on the total weight of the composition. The compositions of the present invention can also include a small amount, about 0.01 to about 4% by weight, of a topical anesthetic, if desired. Typical topical anesthetics include lidocaine, dyclonine, dibucaine, pharmaceutically acceptable salts and mixtures thereof. In one preferred embodiment, the topical anesthetic is about 0.5 percent dyclonine, based on the weight of the composition.

Unless otherwise indicated, each composition is prepared by conventionally admixing the respective indicated components together.

25 **EXAMPLE 1: Topical Prostaglandin E₁ Composition A**
Composition A was prepared as follows.

Part A was formed by dissolving 0.4 parts prostaglandin E₁ (Alprostadil USP) in 5 parts ethyl alcohol. Next, 5 parts dodecyl 2-(N,N-dimethylamino)-propionate were mixed into the alcohol-prostaglandin E₁ solution, followed by 5 parts ethyl laurate.

Part B was prepared starting from a pH 5.5 water/buffer solution. The water/buffer solution was prepared by adding sufficient potassium phosphate monohydrate to purified water to create a 0.1 M solution. The pH of the water/buffer solution was

- 30 -

adjusted to 5.5 with a strong base solution (1 N sodium hydroxide) and a strong acid (1 N phosphoric acid). The buffer solution represented about 80 parts of the total composition.

5 To the buffer solution, was added 0.5 parts ethyl laurate. Next, the locust bean gum (in powder form) was dispersed in the buffer solution and homogenized using a homogenizer. TABLE 1, below, contains a list of ingredients.

10 The resulting composition was a spreadable, semi-solid suitable for application to the skin without the need for supporting devices such as patches and adhesive strips. The composition was both homogenous in appearance and resistant to 15 separation.

Composition A was evaluated for skin penetration using shed snake skin as a model barrier.

Shed snake skin was obtained from the Animal Care Unit of the University of Kansas. With head and tail 20 sections removed, the skin was randomly divided into test sections and then hydrated by soaking.

The samples were then evaluated using Franz-type Diffusion Cells (surface area 1.8 cm^2). Specifically, skin pieces were mounted on top of a 25 receptor cell of a vertical diffusion cell assembly in which a small magnetic bar was inserted and filled with an isotonic buffer. A seal was placed on top of the skin section followed by a donor cell. The two cells were clamped together. Known amounts of the 30 formulations were applied on the bottom of a small capped vial (weight 0.5 grams) which fits exactly to the donor cell to ensure uniform distribution. The vials were placed on the skin in the donor cell. To reduce the evaporation of the ingredients, the donor 35 cell and vial were gently taped together with a water-resistant adhesive band. The cells were transferred to a stirred water bath (32 degrees

- 31 -

Celsius). Samples were withdrawn from the cells each hour for four hours and analyzed for the concentration of prostaglandin E₁, with changes in concentration indicating the amount penetrating.

5 Tests with multiple skin samples yielded data that were averaged.

For a discussion of the use of shed snake skin in the evaluation of drug penetration, see U.S. Patent No. 4,771,004 to Higuchi, which is

10 incorporated here by reference to the extent that it is not inconsistent.

15 The prostaglandin E₁ penetrated quickly at a relatively sustained rate for four hours. The results of the penetration study are presented in TABLE 2, below, and in FIGURE 3.

EXAMPLE 2: Topical Prostaglandin E₁ Composition B

Composition B was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E₁ than Composition A.

20 Despite this increased drug loading, Composition B exhibited a similar semi-solid consistency and homogenous appearance. The penetration of prostaglandin E₁ was measured according to the technique described in Example 1. Composition B

25 provided a relatively fast, sustained delivery of prostaglandin E₁. The results are presented in TABLE 2, below, and in FIGURE 3.

EXAMPLE 3: Topical Prostaglandin E₁ Composition C

Composition C was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E₁ than either Composition A or B. The increased drug loading had little or no effect on the consistency or appearance, which substantially matched that of Compositions A and B. The penetration of prostaglandin E₁ was again measured according to the technique described in Example 1. According to this test, Composition C

- 32 -

also provided a relatively fast, sustained delivery of prostaglandin E₁. The results are presented in TABLE 2, below, and in FIGURE 3.

EXAMPLE 4: Topical Prostaglandin E₁ Composition D

5 Composition D was prepared using the ingredients listed in TABLE 1, below. The level of prostaglandin E₁ was again increased without substantially affecting the favorable consistency and separation resistance. The penetration of
10 prostaglandin E₁ was again measured according to the technique described in Example 1. The results are presented in TABLE 2, below, and in FIGURE 3.

15 **EXAMPLE 5: Topical Prostaglandin E₁ Composition E**

Composition E was prepared using the ingredients listed in TABLE 1, below. To assess the repeatability of compositions according to the present invention, the recipe of Composition D was
20 again applied for Composition E. Repeatability was substantially confirmed by Composition E's favorable, semi-solid consistency and separation resistance. The penetration of prostaglandin E₁ was again measured according to the technique described in Example 1.
25 The prostaglandin E₁ delivery from Composition E was again relatively fast and sustained. The results are presented in TABLE 2, below, and in FIGURE 3.

EXAMPLE 6: Topical Prostaglandin E₁ Composition F

30 The level of prostaglandin E₁ was again increased for Composition F. The specific ingredients are listed in TABLE 1. The favorable consistency and separation resistance was undiminished. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 3.

35 **EXAMPLE 7: Topical Prostaglandin E₁ Composition G**

Composition G was prepared using the ingredients listed in TABLE 1. For Composition G,

the recipe of Composition F was repeated except that the ester component (ester laurate) was omitted and the level of ethanol was increased a corresponding amount. The resulting composition was also a 5 spreadable, semi-solid having a homogenous appearance and resistance to separation. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 3. While still favorable, these 10 results reflect the relative benefit to compositions of the present invention from a lipophilic compound that includes both an ester component and an alcohol component.

TABLE 1: Topical Prostaglandin E₁ Compositions

	Ingredient (wt%)	A	B	C	D	E	F	G
Part A:	prehydrated locust bean gum	3	3	3	3	3	3	3
	water/buffer (pH 5.5)	81	81	81	81	81	81	81
Part B:	sucrose stearate	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	prostaglandin E ₁	0.1	0.2	0.3	0.4	0.4	0.5	0.4
	DDAIP	5	5	5	5	5	5	5
	ethanol	5	5	5	5	5	5	10
	ethyl laurate	5	5	5	5	5	5	-

15

EXAMPLE 8: Comparison of Penetration Profiles

TABLE 2 shows the cumulative amount of prostaglandin E₁ penetrating each hour for 4 hours for each example composition according to the present 20 invention. These data demonstrate the ability of the present invention to delivery prostaglandin E₁ drugs transdermally.

FIGURE 3 is graph generated from the data 25 presented in TABLE 1. Significantly, and well represented in graphical form, compositions according to the present invention deliver effective skin penetration relatively fast and at a sustained rate.

As expected, cumulative penetration increases with increased prostaglandin E₁ loading of the source 30 composition.

TABLE 2: Cumulative Prostaglandin E₁ Penetration (μg/cm²)

Hour	A	B	C	D	E	F	G
1	1.96	3.37	5.47	7.20	7.09	10.38	3.03
2	5.49	9.72	18.06	21.26	16.6	25.03	8.17
3	11.25	18.18	30.34	35.53	28.24	42.18	12.93
4	13.98	23.48	38.49	47.98	41.1	52.13	18.71

5

To further assess the effectiveness of compositions according the present invention, comparative example compositions were prepared. A first comparative example (Comparative Example 1) was prepared with the same recipe as Compositions D and E except that the DDAIP penetration enhancer was omitted. For A second comparative example (Comparative Example 2), the DDAIP was again omitted, but the level of ethanol was increased a corresponding amount. The specific ingredients used are listed in TABLE 3, below.

TABLE 3: Comparative Examples

	Ingredient (wt%)	Comparative Composition 1	Comparative Composition 2
Part A:	prehydrated locust bean gum	3	3
	water/buffer (pH 5.5)	86	81
	sucrose stearate	0.5	0.5
Part B:	prostaglandin E ₁	0.4	0.4
	ethanol	5	10
	ethyl laurate	5	5

20 The penetration of prostaglandin E₁ from was evaluated according to the technique described in Example 1. The results are presented in TABLE 4, below.

Hour	Cumulative Prostaglandin E ₁ Penetration (μg/cm ²)	
	Comparative Composition 1	Comparative Composition 2
1	2.64	1.55
2	4.46	3.69
3	6.59	6.63
4	9.67	11.05

5 The data of TABLE 4 are compared graphically to the example compositions having the same prostaglandin E₁ loading, Compositions D and E. The penetration data demonstrate that compositions according to the present invention benefit greatly 10 from the presence of the DDAIP penetration enhancer.

Example 9

Single Use Double Blind and Open Label Clinical Trials

15 The safety and efficacy of a 0.4% prostaglandin E₁ (prostaglandin E₁ or alprostadil) topical composition (composition D of Example 4 and Table 1, above) was evaluated in a total of 143 men 20 at three study sites. This study consisted of a double-blind, placebo controlled and cross-over portion and an open-label portion.

25 The double-blind placebo controlled portion of the study entered and completed 64 men (Table 5, below). Seventy-nine (79) men entered and completed the open-label portion of the study (Table 5, below). With the results of detailed statistical analyses on this study are outlined in the attached report, summarized below are discussions on the results of 30 the clinical studies.

Inclusion Criteria

1. Males, ages 21-70 years, inclusive.
- 5 2. Documented history of erectile dysfunction, which is defined as the inability to achieve and maintain an erection of sufficient rigidity for sexual intercourse due to psychogenic, neurogenic or vasculogenic, causes during the previous 6 months.
- 10 This includes patients who may still have some erections sufficient for intercourse but not consistently, which is the typical complaint of the age onset, mild to moderate impotent man. The diagnosis of erectile dysfunction will be based on
- 15 medical history and physical examination.

Exclusion Criteria

1. History of urethral stricture or obstruction
- 20 2. Any combination of findings from history, physical examination or screening studies which indicate pre-existing impairment of heart, liver and/or kidney function (such as congestive heart failure, unstable angina or recent acute myocardial infarction, uncontrolled diabetes, for erectile dysfunction of hormonal origin) which in the investigator's opinion could influence the outcome of the study.
- 25 3. History of penile surgery, including penile implant, prostatectomy or cancer of the prostate, penile trauma including paraplegia or quadriplegia.
- 30 4. Any condition which might predispose towards priapism, such as sickle cell anemia, multiple myeloma, or leukemia.
- 35 5. Hypertension, (sitting diastolic pressure >90 or systolic >150) requiring treatment with other

than angiotensin converting enzyme inhibitors (ACE inhibitors).

6. Presence of a sexually transmitted disease as determined by physical examination.

5 7. Use of a cavernosal injection or external erectile device within 4 weeks prior to entering into this study.

10 8. Peyronie's Disease or any palpable fibrous scar or plaque on the penis, evidence of curvature during tumescence and rigidity stimulation or an anomaly of the penis skin or mucosa of the glans.

15 9. Any concomitant medication which are known to interfere with sexual activity such as antidepressants, some antihypertensives, sedatives hormones and some allergy medications.

10. Received any investigational treatment within 30 days of entering into this study.

11. Inability or unwillingness to give informed consent.

20 The patient population in this study consisted of men in the age range of 49 - 70 years old.

Table 5. Patient Enrollment by Study Sites

Portion	Patients Enrolled On Study Sites			Total
	No. 1	No. 2	No. 3	
Double-Blind	30	34	0	64
Open Label	32	8	39	79

25 Clinical efficacy was evaluated from patient history and patient evaluation questionnaires both before and after medication using a six-point classification scale (Table 6). Each patient was given one (1) placebo and one (1) active dose in a crossover manner with a 5 to 7 day wash-off period in the double-blind portion of the study. In the open-label portion the patients were given only one (1) active dose. The clinical supply was packaged in single-dose containers each containing 250mg (net

weight) of cream and 1.0 mg prostaglandin E₁.

The efficacy response rate was determined as the number of men that had erections sufficient for intercourse out of the total number of men. To be considered a success, a score of 8 to 10 must be achieved after administration of the dose or the patient must have had intercourse.

Statistical analysis compared before and after response scores using a paired t-test. A statistically significant difference (P< 0.001) between all before and after dosing scores was found for each group of patients receiving active medication whether in the double-blind portion of the study or the open label portion of the study. Also, a statistically significance was seen between the active and placebo groups per study site.

Table 6. Six-Point Classification Scale for Assessing the Severity of Male Erectile Dysfunction (Impotence)

Classification	Definition
0	Severe impotence with no function
2	Severe impotence with very little function
4	Severe impotence with some function
6	Mild to moderate impotence
8	Not impotent but has some loss of function
10	Not impotent with full function

Table 7. Patient Enrollment by Impotence Classification

	Severe	Mild to Moderate	Not Impotent	
Double-Blind	39	25	0	64
Open Label	63	16	0	79
Total Patients	102	41	0	143

The topical prostaglandin E₁ composition was found to be safe and effective in impotent men with the moderate to severe impotence. The efficacy rate was 64.7% (66/102 patients) in severely impotent men and 100% (41/41 patients) in mild to moderately impotent men. The overall clinical efficacy rate for the study is 74.8% (107/143 patients) as shown in

Table 8, below.

Table 8. Overall Clinical Efficacy Rates

	Double-Blind Portion	Open-Label Portion	Combined Overall Rate
Placebo	4.7% (3/64)	-	4.7% (3/64)
Active	87.5% (56/64) P<0.001	64.6% (51/79)	74.8% (107/143) P<0.001

The prostaglandin E₁ topical composition was
5 extremely effective (100%) in the mild to moderate
impotent patient population. The mild to moderate
impotence class is the most prevalent class and is
estimated to represent 70% of all erectile
dysfunction complaints. The product was also very
10 effective (64.7%) in the severely impotent study
population.

A placebo efficacy response was seen in
only 3 of 64 (4.7%) patients studied in the double-
blind portion of the study. This is far below the
15 expected rate of approximately 10% as reported in
other clinical studies. This low rate is perhaps due
to the fact that the majority (63%) of the patients
enrolled in the double-blind portion of the study
were classified with severe impotence. While 17 of
20 64 (26.6%) patients showed improvement with the
placebo, only three (3) of those patients had
sufficient improvement to be assessed as efficacious
(8 or 10 on the classification scale).

25

Table 9. Clinical Efficacy Rates by Impotence Classification
Study Sites

	Portion	No. 1	No. 2	No. 3	Combined Efficacy
Severely Impotent	Double-Blind	85.7% (24/28)	63.6% (7/11)	No Patients Entered	79.5% (31/39)
	Open Label	72.2% (13/18)	33.3% (2/6)	51.3% (20/39)	55.6% (35/63)
Mild to Moderate Impotence	Double-Blind	100% (2/2)	100% (23/23)	No Patients Entered	100% (25/25)
	Open Label	100% ((14/14)	100% (2/2)	No Patients Entered	100% (16/16)

- 40 -

The open label efficacy rate was lower than the double-blind efficacy rate (Table 9). This was primarily due to the enrollment of a relatively high number of severely impotent men in the open-label portion of the study as compared to the double-blind portion. (Table 8) Of the men enrolled in the open label portion of the study, 79.7% (63/79) were assessed as severely impotent while only 60.9% (39/64) were assessed as severely impotent on entering the double-blind portion. The efficacy rate among the severely impotent population is expected to be lower because by definition these men have little or no function. Practically, it is expected to be more difficult to move the impotence classification from 0, 2 or 4 up to 8 or 10. While most of the severely impotent men showed significant improvement, 36 men (36/102 or 35.3%) did not have sufficient improvement to be classified as efficacious.

Adverse events observed in this study were mild transient burning or tingling at the application site. No systemic toxic side effects were observed.

Also, none of the spouses involved in the studies reported adverse events. None of the patients dropped out of the study or were lost to follow-up

25

Example 10
Multiple Use Open Label Clinical Trial

30 The safety and efficacy of a 0.4% prostaglandin E₁ topical composition (composition D of Example 4 and Table 1, above) was evaluated in an additional study of a total of 56 men at three study sites. Fifty-six (56) male patients with organic 35 erectile dysfunction entered and completed the study. Patients were classified into groups based on their responses to the International Index of

- 41 -

Erectile Dysfunction (IIEF) and the pre dose Sexual Encounter Profile (SEP). Forty-nine (49) patients were classified as having mild to moderate erectile dysfunction and 7 patients were classified as having 5 severe erectile dysfunction. Each patient was asked to use from 3 to 10 doses of medication over a four week period in a multiple use, in-home study. The overall efficacy rate for the mild to moderate group was 75%. The results of this study were 10 consistent with the combined overall efficacy rate reported above in Example 9. None of the patients dropped out of this multiple use study and no severe adverse events were noted.

15 Inclusion Criteria

1. Males, ages 21-70 years, inclusive.
2. Documented history of erectile dysfunction, which is defined as the inability to 20 achieve and maintain an erection of sufficient rigidity for sexual intercourse due to psychogenic, neurogenic or vasculogenic, causes during the previous 6 months. This includes patients who may still have some erections sufficient for intercourse 25 but not consistently, which is the typical complaint of the age onset, mild to moderate impotent man. The diagnosis of erectile dysfunction will be based on medical history and physical examination.

30 Exclusion Criteria

1. History of urethral stricture or obstruction.
2. Any combination of findings from history, 35 physical examination or screening studies which indicate pre-existing impairment of heart, liver and/or kidney function (such as congestive heart

- 42 -

failure, unstable angina or recent acute myocardial infarction, uncontrolled diabetes, for erectile dysfunction of hormonal origin) which in the investigator's opinion could influence the outcome 5 of the study.

3. History of penile surgery, including penile implant, prostatectomy or cancer of the prostate, penile trauma including paraplegia or quadriplegia.

10 4. Any condition which might predispose towards priapism, such as sickle cell anemia, multiple myeloma, or leukemia.

15 5. Hypertension, (sitting diastolic pressure >90 or systolic >150) requiring treatment with other than angiotensin converting enzyme inhibitors (ACE inhibitors).

6. Presence of a sexually transmitted disease as determined by physical examination.

20 7. Use of a cavernosal injection or external erectile device within 4 weeks prior to entering into this study.

25 8. Peyronie's Disease or any palpable fibrous scar or plaque on the penis, evidence of curvature during tumescence and rigidity stimulation or an anomaly of the penis skin or mucosa of the glans.

9. Any concomitant medication which are known to interfere with sexual activity such as antidepressants, some antihypertensives, sedatives hormones and some allergy medications.

30 10. Received any investigational treatment within 30 days of entering into this study.

11. Inability or unwillingness to give informed consent.

35 The patient population in this study consisted of men in the age range of 49- 70 years old.

- 43 -

Table 10. Patient Enrollment by Study Sites**Patients Enrolled On Study Sites**

No. 1	No. 2	No. 3	Total
22	13	21	56

Clinical efficacy was evaluated from patient history and patient evaluation questionnaires both before and after medication using the International Index of Erectile Function (Table 11) and the Sexual Encounter Profile (SEP) six-point classification scale (Table 12). Each patient was given 10 active doses and asked to take the medication home and attempt intercourse as many times as possible over a 4 week period. The medication was packaged in a specially designed single dose applicator.

Table 11. International Index of Erectile Function

Classification	Definition
<12	Severe impotence with no function
12-18	Mild Impotence with very little function
18-24	Moderate Impotence with some function
24+	No dysfunction

15

Table 12
Sexual Encounter Profile(SEP): Six-Point Classification Scale for Assessing the Severity of Male Erectile Dysfunction (Impotence)

Classification	Definition
0	Severe impotence with no function
2	Moderate Impotence with very little function
4	Moderate Impotence with some function
6	Mild Impotence
8	Not impotent but has some loss of function
10	Not impotent with full function

The efficacy response rate was determined as the number of intercourse successes out of the total number of intercourse attempts. To be considered a success, a SEP score of 8 to 10 must be achieved after administration of the dose or the patient must have had satisfactory sexual intercourse. Statistical analysis compared before and after response scores using Chi Square statistics. A statistically significant difference ($P < 0.001$) between before and after dosing scores was found for each group of patients receiving active medication.

Table 13. Patient Enrollment by Impotence Classification

Patients	Severe	Mild to Moderate	Total
	7	49	56

15

Table 14. Efficacy per Patient Group

	Efficacy by Patients		Efficacy by Attempts	
Mild to Moderate	36/49	(74%)	178/239	(75%)
Severe	4/7	(57%)	16/36	(44%)

As previously discussed, the prostaglandin E₁ topical composition was extremely effective (75%) in the mild to moderate impotent patient population.

The mild to moderate impotence class is the most prevalent class and is estimated to represent 70% of all erectile dysfunction complaints. The product was less effective (44%) in the severely impotent study population, however, there was a statistically significant difference between the before and after treatment scores in this group. Even though all of the men in the severe group were totally without any erectile function before the study, 4 of the 7 men (57%) had successful intercourse from at least 3 out

- 45 -

of the 10 doses.

Adverse events observed in this study were mild transient burning or tingling at the application site. No systemic toxic side effects 5 were observed. Also, none of the spouses involved in the studies reported adverse events. None of the patients dropped out of the study or were lost to follow-up.


The results of this clinical indicate the use of the 10 prostaglandin E₁ 0.4% topical composition of the present invention for the treatment of mild, moderate to severe impotence is safe and efficacious.

15 The foregoing specification is intended as illustrative and is not to be taken as limiting. Still other variations within the spirit and the scope of the invention are possible and will readily present themselves to those skilled in the art.

We Claim:

1. A method of treating erectile dysfunction in a patient needing such treatment comprising:
 - 5 applying in the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1 composition comprising prostaglandin E₁;
 - 10 a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted)-alkanol alkanoate, pharmaceutically acceptable salts thereof and a mixture thereof;
 - 15 a polysaccharide gum;
 - 20 a lipophilic compound which is a member of the group consisting of an aliphatic C₁ to C₈ alcohol, an aliphatic C₈ to C₃₀ ester, and a mixture thereof; and
 - 25 an acidic buffer system.
2. The method of claim 1 wherein at least 50% of the applied amount of the prostaglandin E1 composition is retained in the fossa navicularis.
3. The method of claim 1 wherein at least 80% of the applied amount of the prostaglandin E1 composition is retained in the fossa navicularis.
4. The method of claim 1 wherein the prostaglandin E1 composition is applied in the fossa navicularis using an applicator that ends within the limits of the fossa navicularis when placing the composition.
- 30 5. The method of claim 4 wherein the applicator extends less than one centimeter into the penis.
6. The method in accordance with claim 1 wherein said penetration enhancer is a alkyl-2-(N,N-disubstituted amino)-alkanoate represented by the formula:


- 47 -



wherein n is an integer having a value in the range of about 4 to about 18; R is a member of the group consisting of hydrogen, C₁ to C₇, alkyl, benzyl and phenyl; R₁ and R₂ are members of the group consisting of hydrogen and C₁ to C₇, alkyl; and R₃ and R₄ are members of the group consisting of hydrogen, methyl and ethyl.

7. The method in accordance with claim 1
10 wherein said penetration enhancer is selected from the group consisting of a C₄ to C₁₈ alkyl (N,N-disubstituted amino)-acetate, a dodecyl (N,N-dimethylamino)-acetate and a dodecyl 2-(N,N-dimethylamino)-propionate.

15 8. The method in accordance with claim 1
wherein said penetration enhancer is an
(N,N-disubstituted amino)-alkanol alkanoate
represented by the formula:



20

wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 are members of the group consisting of hydrogen, C_1 to C_8 alkyl, and C_1 to C_8 aryl; and R_8 is

a member of the group consisting of hydrogen, hydroxyl, C₁ to C₈ alkyl, and C₁ to C₈ aryl.

9. The method in accordance with claim 1 wherein said penetration enhancer is a C₅ to C₁₈ carboxylic acid ester.

10. The method in accordance with claim 1 wherein said penetration enhancer is selected from the group consisting of

1- (N,N-dimethylamino)-2-propanol dodecanoate,
10 1- (N,N-dimethylamino)-2-propanol myristate, and
1- (N,N-dimethylamino)-2-propanol oleate.

11. The method in accordance with claim 1 wherein said polysaccharide gum is selected from the group consisting of galactomannan gums and modified galactomannan gums.

12. The method in accordance with claim 11 wherein said galactomannan gum is a locust bean gum.

13. The method in accordance with claim 11 wherein said galactomannan gum is a guar gum.

14. The method in accordance with claim 11 wherein said modified galactomannan gum is a modified guar gum.

15. The method in accordance with claim 1 wherein said lipophilic compound is ethanol.

16. The method in accordance with claim 1 wherein said lipophilic compound is a polyol aliphatic alcohol.

17. The method in accordance with claim 1 wherein said lipophilic compound is isopropyl myristate.

18. The method in accordance with claim 1 wherein said lipophilic compound is ethyl laurate.

19. The method in accordance with claim 1 wherein said lipophilic compound is a mixture of ethanol and isopropyl myristate.

20. The method in accordance with claim 1 wherein said lipophilic compound is a mixture of

ethanol and ethyl laurate.

21. The method in accordance with claim 1 wherein said lipophilic compound comprises at least one aliphatic C₈ to C₃₀ ester.

5 22. The method in accordance with claim 1 wherein said lipophilic compound comprises at least one glyceryl ester selected from the group consisting monoglycerides, diglycerides, triglycerides, and mixtures thereof.

10 23. The method in accordance with claim 22 wherein said lipophilic compound comprises at least one glyceryl ester selected from the group consisting of glyceryl monooleate, triolein, trimyristin, tristearin, and mixtures thereof.

15 24. The method in accordance with claim 1 wherein said acidic buffer system is capable of providing a buffered pH value for said composition in the range of about 3 to about 6.5.

20 25. The method in accordance with claim 1 wherein said penetration enhancer is a dodecyl 2- (N,N-dimethylamino) -propionate, said polysaccharide gum is a locust bean gum, and said lipophilic compound is a mixture of ethanol and ethyl laurate.

25 26. A method in accordance with claim 1, wherein the composition comprises 0.5 to 5 weight percent locust bean gum, 0.5 to 25 weight percent dodecyl 2- (N,N-dimethylamino) -propionate, 0.5 to 80 weight percent ethanol, and 0.5 to 80 weight percent isopropyl myristate, based on the total 30 weight of the composition.

27. A method in accordance with claim 1, wherein the composition comprises 0.5 to 5 weight percent locust bean gum, 0.5 to 5 weight percent dodecyl 2- (N,N-dimethylamino) -propionate, 0.5 to 25 weight percent ethanol, and 0.5 to 25 weight percent ethyl laurate, based on the total weight of 35 the composition.

28. A method in accordance with claim 1, wherein the composition further comprises an emulsifier selected from the group consisting of sucrose esters, polyoxyethylene sorbitan esters, long chain alcohols, and glyceryl esters.

29. A method in accordance with claim 28 wherein said emulsifier is a sucrose stearate.

30. A method in accordance with claim 28 wherein said emulsifier comprises at least one glyceryl ester selected from the group consisting of glyceryl monooleate, triolein, trimyristin, tristearin, and mixtures thereof.

31. A method in accordance with claim 1, wherein the composition further comprises a fragrance.

32. A method in accordance with claim 1, wherein the composition further comprises up to about 5 percent myrtenol, based on the total weight of the composition.

33. A method in accordance with claim 1, wherein the composition further comprises a preservative.

34. A method in accordance with claim 1, wherein the composition further comprises a topical anesthetic.

35. A method of treating erectile dysfunction in a patient needing such treatment comprising:

30 placing in the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1 composition comprising prostaglandin E₁;

35 a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted)-alkanol alkanoate, and a mixture thereof;

- 51 -

a polyacrylic acid polymer;
a lipophilic compound which is a member of
the group consisting of an aliphatic C₁ to C₈ alcohol,
an aliphatic C₈ to C₃₀ ester, and a mixture thereof;
5 and

an acidic buffer system.

36. A method in accordance with claim 35
wherein said polyacrylic acid polymer is a carbomer.

37. An applicator suitable for placing an
10 effective erection-inducing amount of a semisolid
composition into the fossa navicularis of a patient
needing treatment, the composition comprising:

prostaglandin E₁;

15 a skin penetration enhancer which is a
member of the group consisting of an alkyl-2-
(N,N-disubstituted amino)-alkanoate, an (N,N-
disubstituted)-alkanol alkanoate, pharmaceutically
acceptable salts thereof and a mixture thereof;

a polysaccharide gum;

20 a lipophilic compound which is a member of
the group consisting of an aliphatic C₁ to C₈ alcohol,
an aliphatic C₈ to C₃₀ ester, and a mixture thereof;
and

an acidic buffer system.

25 38. The applicator of claim 37, wherein
the composition further comprises a vasoactive agent
selected from the group consisting of nitroglycerin,
isosorbide dinitrate, erythrityl tetranitrate, amyl
nitrate, sodium nitroprusside, molsidomine,
30 linsidomine chlorhydrate, S-nitroso-N-acetyl-d,l-
penicillamine, phenoxybenzamine, dibenamine,
doxazosin, terazosin, phentolamine, tolazoline,
prazosin, trimazosin, alfuzosin, tamsulosin,
indoramin, acetergamine, brazergoline, bromerguride,
35 cianergoline, delorgotriile, disulergine, ergonovine
maleate, ergotamine tartrate, etisulergine,
lergotriile, lysergide, mesulergine, metergoline,

- 52 -

5 metergотamine, nicergoline, pergolide, propisergide, proterguride, terguride, diazoxide, hydralazine, minoxidil, nimodepine, pinacidil, cyclandelate, dipyridamole, isoxsuprine, chlorpromazine, haloperidol, yohimbine, trazodone, and mixture, and mixtures thereof.

39. A prostaglandin E₁ composition comprising prostaglandin E₁ suitable for administration in the fossa navicularis comprising:

10 a modified polysaccharide gum; a prostaglandin selected from the group consisting of PGE₁, pharmaceutically acceptable salts thereof, lower alkyl esters thereof and mixtures thereof;

15 about 0.5 percent to about 10 percent DDAIP or salts thereof, based on the total weight of the composition;

20 about 0.5 percent to about 10 percent based on the total weight of the composition of a lower alcohol selected from the group consisting of ethanol, propanol, isopropanol and mixtures thereof;

25 about 0.5 percent to about 10 percent of an ester selected from the group consisting of ethyl laurate, isopropyl myristate, isopropyl laurate and mixtures thereof, based on the total weight of the composition; and

an acidic buffer system.

40. The composition of claim 39, further comprising an emulsifier selected from the group consisting of sucrose esters, polyoxyethylene sorbitan esters, long chain alcohols, and glyceryl esters.

41. The composition of claim 40 wherein said emulsifier is a sucrose stearate.

42. The composition of claim 40 wherein said emulsifier comprises at least one glyceryl ester selected from the group consisting of glyceryl

- 53 -

monooleate, triolein, trimyristin, tristearin, and mixtures thereof.

43. The composition of claim 39 wherein said composition further comprises a fragrance.

5 44. The composition of claim 39 wherein said composition further comprises up to about 5 percent myrtenol, based on the total weight of the composition.

10 45. The composition of claim 39 wherein said composition further comprises a preservative.

46. The composition of claim 39 wherein said composition further comprises a topical anesthetic.

15 47. The use of a composition in accordance with any one of claims 39 to 46 for the preparation of a pharmaceutical composition for transdermal or transmucosal administration.

20 48. The use of a composition in accordance with any one of claims 39 to 46 for the preparation of a pharmaceutical composition for intranavicular administration.

1/3




Fig. 1




Fig. 2

2/3




Fig. 3

3/3




Fig. 4

INTERNATIONAL SEARCH REPORT

In international Application No
PCT/US 01/00852

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/557 A61K9/00 A61K47/18 A61P15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 65303 A (GYURIK ROBERT J ;KRAUSER SCOTT F (US); MACROCHEM CORP (US); SAMOUR) 23 December 1999 (1999-12-23) abstract page 1, line 5 - line 10 page 12, line 10 -page 13, line 23 claims 1-20	1-48
Y	EP 0 357 581 A (AMSU LTD) 7 March 1990 (1990-03-07) abstract page 2, line 3 - line 5 page 3, line 11 - line 14 claims 1-51	1-48
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 May 2001

Date of mailing of the International search report

05/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Taylor, G.M.

INTERNATIONAL SEARCH REPORT

In **International Application No**
PCT/US 01/00852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 69469 A (BUYUKTIMKIN NADIR ;NEXMED HOLDINGS INC (US); YEAGER JAMES L (US);) 23 November 2000 (2000-11-23) abstract page 2, line 35 -page 3, line 17 page 3, line 28 page 3, line 32 -page 4, line 3 claims 1-32 figures 1,2 ---	1-48
P, X	WO 00 33825 A (NEXMED HOLDINGS INC) 15 June 2000 (2000-06-15) abstract page 1, line 10 - line 14 claims 1-72 ---	1-48
A	US 4 980 378 A (WONG OOI ET AL) 25 December 1990 (1990-12-25) cited in the application abstract examples 1-8 claims 1-15 ---	1-48
A	GB 1 367 550 A (UPJOHN CO) 18 September 1974 (1974-09-18) column 1, line 24 - line 30 examples 1-3 claims 1-7 ---	1-48
P, A	US 6 102 849 A (HAKAC JOHN R) 15 August 2000 (2000-08-15) abstract ---	1-48

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.
PCT/US 01/00852

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9965303	A 23-12-1999	US 5942545 A		24-08-1999
		AU 7838798 A		05-01-2000
		BR 9811797 A		26-09-2000
		EP 1026947 A		16-08-2000
		JP 2000511944 T		12-09-2000
		NO 20000157 A		09-02-2000
EP 0357581	A 07-03-1990	SE 463851 B		04-02-1991
		AT 91886 T		15-08-1993
		AU 638414 B		01-07-1993
		AU 4199489 A		02-04-1990
		CA 1335346 A		25-04-1995
		DE 68907909 D		02-09-1993
		DE 68907909 T		23-12-1993
		DK 36491 A		01-03-1991
		EP 0432199 A		19-06-1991
		ES 2055677 T		01-09-1994
		FI 102454 B		15-12-1998
		GR 90300093 T		27-09-1991
		IE 62587 B		08-02-1995
		JP 7091199 B		04-10-1995
		JP 4501707 T		26-03-1992
		NO 301046 B		08-09-1997
		NZ 230400 A		29-01-1992
		SE 8803087 A		03-03-1990
		WO 9002545 A		22-03-1990
		US 5849803 A		15-12-1998
		US 5942512 A		24-08-1999
		US 5843961 A		01-12-1998
		US 5886039 A		23-03-1999
		ZA 8906681 A		27-06-1990
WO 0069469	A 23-11-2000	US 6046244 A		04-04-2000
		CN 1284862 T		21-02-2001
		EP 1028708 A		23-08-2000
		TR 200002158 T		21-11-2000
		WO 9922714 A		14-05-1999
WO 0033825	A 15-06-2000	AU 2358600 A		26-06-2000
US 4980378	A 25-12-1990	US 5082866 A		21-01-1992
GB 1367550	A 18-09-1974	AU 474378 B		22-07-1976
		AU 4777872 A		26-04-1974
		BE 790840 A		30-04-1973
		DE 2251713 A		10-05-1973
		FR 2158405 A		15-06-1973
		IL 40517 A		13-03-1975
		NL 7214204 A		03-05-1973
		PH 9756 A		12-03-1976
		US 3829579 A		13-08-1974
		ZA 7207077 A		27-06-1973
US 6102849	A 15-08-2000	NONE		